Market Trends– category –
-
CRISPR Therapeutics Demonstrates Future Potential with Casgevy Approval, Leading Gene-Editing Market Through Pipeline Diversification
Intellectia.AI USA Overview CRISPR Therapeutics has established market leadership with the FDA approval of Casgevy, its gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. In 2025, 64 patients receive... -
Cynata Therapeutics to Announce Phase 3 iPSC-Derived MSC Results for Knee Osteoarthritis in June; Acute GVHD Phase 2 Nears Completion
Regen Report Australia Overview Cynata Therapeutics is set to release top-line results from its Phase 3 clinical trial, 'STOP-OA,' for knee osteoarthritis (KOA) using iPSC-derived mesenchymal stem cells (iPSC-MSC). The KOA trial database... -
Japan Nears Approval of BioCardia’s CardiAMP Heart Failure Cell Therapy: PMDA Issues Consultation Record Supporting Regulatory Submission
Longevity.Technology Japan Overview Japan has moved closer to approving BioCardia's CardiAMP cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF). Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued... -
High Volume of CRISPR Therapeutics Call Options Reflects Strong Market Confidence in Gene-Editing Pipeline
MarketBeat USA Overview On June 4, 2026, CRISPR Therapeutics (NASDAQ:CRSP) experienced exceptionally high call option trading volume, indicating robust investor interest in the company. This active trading reflects sustained confidence f... -
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ... -
OpenAI and Anthropic Dominate AI Revenue, with Anthropic Approaching $30B Annually, as Information Disclosure Asymmetry Becomes Industry Challenge
PR Newswire USA Overview The 2026 AI Company Comms Study by 5WPR reveals that OpenAI and Anthropic are dominating AI revenue, with Anthropic's annualized revenue reaching approximately $30 billion in April 2026, surpassing OpenAI's $25 b... -
A Quarter of Enterprise AI Agent Deployments Fail ROI Targets, Citing Governance and IAM Deficiencies
ITSM.tools 他 UK Overview New 2026 research indicates that 25% of AI agent deployments in large UK enterprises are failing to achieve their expected ROI, primarily due to critical governance gaps. Key challenges include the absence of pu... -
Sustainable Holiday Packaging Trends: Bio-Plastics Create Recycling Stream Chaos, Driving Return to Paper
Holidaypacfactory Europe Overview Sustainable holiday packaging trends for 2026 face an unforeseen challenge as bio-plastics, particularly PLA and PHA, disrupt recycling streams. A survey across the UK and Germany reveals 71% of shoppers... -
Fujitsu Announces ¥3 Trillion ($19 Billion) Investment in AI and Quantum Technologies Over Next Decade
Let's Data Science (citing News On Japan) Japan Overview Fujitsu has unveiled a long-term management vision through FY2035, pledging approximately ¥3 trillion (over $19 billion) over the next decade into growth businesses centered on AI ...
